Rheums Speak - RA Treatment Survey RheumNow's August 2025 “Live Vote” surveys will examine Rheumatologist impressio

Tweet Author

Tweet Content

Rheums Speak - RA Treatment Survey RheumNow's August 2025 “Live Vote” surveys will examine Rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis. https://t.co/hJSQ5mMJ6b https://t.co/466wOjTSGS

Links

https://buff.ly/yYSOrME

COVID Vaccine study in rheum pts on JAKi (n 22) or TNFi (n 16) Showing 50% response in JAKi and 81% w/ TNFi Rx. Pt P

Tweet Author

RheumNow

Tweet Content

COVID Vaccine study in rheum pts on JAKi (n 22) or TNFi (n 16) Showing 50% response in JAKi and 81% w/ TNFi Rx. Pt PBMCs were stim by SAR-CoV2 spike proteins & CD4+ T cells IFNγ production as Pos. response. Do JAKi impair COVID-19 Vax responses? https://t.co/dZAktwrytf https://t.co/mjkBfcGcfD

Links

Comparison of T cell response to vaccination in rheumatic patients treated with… https://buff.ly/yT3BIOv

6 August 2025

Smoking and the Global Burden of Rheumatoid Arthritis

Detailed analysis of the Global Burden of Disease (GBD) 2021 database shows that tobacco and smoking is one of the most significant environmental risk factors for Rheumatoid Arthritis (RA) over the last 20 years.

This study utilized the Global Burden of Disease (GBD) 2021 database to analyze the burden of RA attributable to smoking, specifically looking at Deaths, Disability-Adjusted Life Years (DALYs), Years Lived with Disability (YLDs), Years of Life Lost (YLLs), and the Socio-Demographic Index (SDI).

6 August 2025

RA leads to ILD: but ILD does not lead to RA

Rheumatoid arthritis is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear.

Full read overview of Immune Checkpoint Inhibitors and their downside - immune related Adverse Events https://t.co/h1

Tweet Author

RheumNow

Tweet Content

Full read overview of Immune Checkpoint Inhibitors and their downside - immune related Adverse Events https://t.co/h1AzFaGVMz https://t.co/s75UdhE1HK

Links

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strate… https://buff.ly/r7OSjgj

Survey of 39 Spanish rheumatologists (mean age 50 yrs, 9.6 yrs in practice) finds that while 79% agreed on the importanc

Tweet Author

RheumNow

Tweet Content

Survey of 39 Spanish rheumatologists (mean age 50 yrs, 9.6 yrs in practice) finds that while 79% agreed on the importance of using Patient-Reported Outcome Measures (PROMs), only 28% use them routinely (mostly pain, VAS, HAQ) - reason? Time! https://t.co/YnZBXlK24M https://t.co/a8W52XO8jh

Links

Use of Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis … https://buff.ly/w00g4yZ

Japans IORRA study of 10,613 RA pts (2007-21) - 915 deaths from cancer (28%), lung Dz (22%), CV Dz (16%). Protective Rx

Tweet Author

RheumNow

Tweet Content

Japans IORRA study of 10,613 RA pts (2007-21) - 915 deaths from cancer (28%), lung Dz (22%), CV Dz (16%). Protective Rx were MTX and bDMARDs, while even low-dose glucocorticoids showed increased mortality risk. https://t.co/lV5WmC5l1X https://t.co/QncyqXSRE9

Links

Mortality and risk factors in Japanese patients with rheumatoid arthritis: a 14… https://buff.ly/g1IHzj0

AMN Healthcare report on MD salaries -- high demand for specialist MDs w/ RHEUM the 7th Most In-Demand. 2024/205 Rheum w

Tweet Author

RheumNow

Tweet Content

AMN Healthcare report on MD salaries -- high demand for specialist MDs w/ RHEUM the 7th Most In-Demand. 2024/205 Rheum were low of $214K, a high of $450K, median of $341,000. Avg salary for NPs is $180K up from $164,000 last year, a 9.6% increase. https://t.co/NcmwrMxpKr https://t.co/a86NvQhZry

Links

Rheumatology Salaries Remain Low | RheumNow https://buff.ly/RZrMFSL

Retrospective review of 9 #RA pts w/ elevated liver enzymes who were Rx w/ TNF inhibitor (4 adalimumab, 5 etanercept; 78

Tweet Author

RheumNow

Tweet Content

Retrospective review of 9 #RA pts w/ elevated liver enzymes who were Rx w/ TNF inhibitor (4 adalimumab, 5 etanercept; 78% female, median BMI 37). Over 3 yrs F/U, LFTs declined, fibrosis scores (FIB-4) signif decreased; albumin & bilirubin remained stable https://t.co/Hcwa3qaupv https://t.co/OwGY5jxxyZ

Links

https://buff.ly/a1fNznZ

Potentially novel RA vaccine of recombinant HLA-DRB1 04:01 bound to type II collagen (COL2) peptide COL2259-273 that was

Tweet Author

RheumNow

Tweet Content

Potentially novel RA vaccine of recombinant HLA-DRB1 04:01 bound to type II collagen (COL2) peptide COL2259-273 that was chemically modified at glycine position 265 & shows to suppress collagen induced arthritis in human DRB1 04:01-expressing mice https://t.co/TtBt49DQDa https://t.co/qMXzmvNc1b

Links

Tolerogenic antigen-specific vaccine induces VISTA-enriched regulatory T cells … https://buff.ly/LoPipTw

Topics

Rheums Speak - RA Treatment Survey RheumNow's August 2025 “Live Vote” surveys will examine Rheumatologist impressio

COVID Vaccine study in rheum pts on JAKi (n 22) or TNFi (n 16) Showing 50% response in JAKi and 81% w/ TNFi Rx. Pt P

Full read overview of Immune Checkpoint Inhibitors and their downside - immune related Adverse Events https://t.co/h1

Survey of 39 Spanish rheumatologists (mean age 50 yrs, 9.6 yrs in practice) finds that while 79% agreed on the importanc

Japans IORRA study of 10,613 RA pts (2007-21) - 915 deaths from cancer (28%), lung Dz (22%), CV Dz (16%). Protective Rx

AMN Healthcare report on MD salaries -- high demand for specialist MDs w/ RHEUM the 7th Most In-Demand. 2024/205 Rheum w

Retrospective review of 9 #RA pts w/ elevated liver enzymes who were Rx w/ TNF inhibitor (4 adalimumab, 5 etanercept; 78

Potentially novel RA vaccine of recombinant HLA-DRB1 04:01 bound to type II collagen (COL2) peptide COL2259-273 that was

Do you get our email newsletter?